Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall

Next Previous
Trial Profile

A Multicenter Randomized, Open-Label Phase II/III Study, To Compare The Efficacy Of NBTXR3, Implanted As Intratumor Injection And Activated By Radiotherapy, Versus Radiotherapy Alone In Patients With Locally Advanced Soft Tissue Sarcoma Of The Extremity And Trunk Wall

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 10 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hafnium oxide (Primary)
  • Indications Soft tissue sarcoma
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms Act.in.sarc
  • Sponsors Nanobiotix; PharmaEngine

Most Recent Events

  • 28 Sep 2022 Final results of Safety and Health-Related Quality of LIfe of the Phase 2/3 Act.In.Sarc Study published in the International Journal of Radiation Oncology, Biology, Physics
  • 13 Sep 2022 Results of an analysis assessing feasibility and safety from phase I trials: NCT02379845, NCT01946867, NCT02721056, NCT03589339, NCT04484909, NCT04615013 and NCT02805894 presented at the 47th European Society for Medical Oncology Congress
  • 06 Oct 2021 According to a Nanobiotix media release, data will be presented at the 2021 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top